Detalhe da pesquisa
1.
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Am J Respir Crit Care Med;
204(1): 64-73, 2021 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33600738
2.
Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
Am J Respir Crit Care Med;
201(2): 188-197, 2020 01 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31601120
3.
Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death.
Eur Respir J;
53(3)2019 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30578399
4.
Relationship between gender and survival in a real-life cohort of patients with COPD.
Respir Res;
20(1): 191, 2019 Aug 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31439045
5.
Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients.
BMC Pulm Med;
19(1): 127, 2019 Jul 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31299936
6.
A simple algorithm for the identification of clinical COPD phenotypes.
Eur Respir J;
50(5)2017 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29097431
7.
Reply to Kuek et al.: Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary Disease.
Am J Respir Crit Care Med;
204(3): 372-374, 2021 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33951399
8.
Phenotypes influencing low physical activity in maintenance dialysis.
J Ren Nutr;
25(1): 31-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25304464
9.
Tiotropium might improve survival in subjects with COPD at high risk of mortality.
Respir Res;
15: 64, 2014 Jun 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24913266
10.
Impact of gender on COPD expression in a real-life cohort.
Respir Res;
15: 20, 2014 Feb 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24533770
11.
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
Ann Am Thorac Soc;
2024 Apr 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38579175
12.
Association between occupational exposure and the clinical characteristics of COPD.
BMC Public Health;
12: 302, 2012 Apr 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22537093
13.
Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis.
J Cyst Fibros;
21(1): 155-159, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34183285
14.
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
J Cyst Fibros;
21(3): 489-496, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35123901
15.
Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD.
Int J Chron Obstruct Pulmon Dis;
16: 1275-1284, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34007166
16.
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.
J Cyst Fibros;
20(2): 220-227, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32591294
17.
Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment.
Eur Respir J;
45(1): 260-2, 2015 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25359339
18.
Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?
Eur Respir J;
43(4): 1201-3, 2014 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24176996
19.
Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities.
Int J Chron Obstruct Pulmon Dis;
14: 1399-1410, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31308646
20.
Clinical COPD phenotypes identified by cluster analysis: validation with mortality.
Eur Respir J;
40(2): 495-6, 2012 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22855468